Schering Sees No Impact From Imports; Not Attractive To “Parallel Traders”
Executive Summary
Schering-Plough sees one advantage to operating as a smaller pharmaceutical player: little or no impact from a potential U.S.-sanctioned drug importation policy
You may also be interested in...
Senate GOP Import Bill Will Start With Canada, Leave Expansion Up To FDA
The Senate Republican leadership's reimportation bill will focus on wholesale imports from Canada and leave any decision about future expansions in parallel trade up to FDA
AARP Supports Canadian Imports To Place “Downward Pressure” On Rx Costs
AARP is endorsing prescription drug reimportation from Canada as a measure to help control the cost of drugs
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011